Ibrahim Aldoss, MD
Enriched profileAssociate Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation · City of Hope National Medical Center
Ibrahim Aldoss is Associate Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope National Medical Center. OpenAlex indexes 562 publications with 8,819 citations (h-index 49); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Ibrahim Aldoss, M.D., is Associate Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope National Medical Center / Comprehensive Cancer Center, Duarte, CA. The public record shows 562 publications with 8,819 citations (h-index 49), centered on Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, CAR-T cell therapy research. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 27 companies, 1 NIH-funded awards (2022–2026).
- Most recent indexed publication: 2026 · British journal of haematology
- Top research focus: Acute Lymphoblastic Leukemia research
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 27 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 53 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 159.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
Sponsor: SWOG Cancer Research Network
- Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Sponsor: City of Hope Medical Center
Industry payments
Updated 27 Aug 2026
27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year202510 payments$15,035openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202511 payments$12,897openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year20254 payments$11,868openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Thalidomide Analog100%Revlimid100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
Congress activity
Updated 27 Aug 2026
151 congress contributions (2010–2025) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Abstract 14: Molecular drivers of lineage bias in TP53-mutant therapy-related acute leukemias
AACR Annual Meeting
AACR2025Co-author - MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis.
ASCO Annual Meeting
ASCO2025Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy.
British journal of haematology
Article2026 - Incorporating ALL Biology into Treatment Decisions: Next Steps toward Targeted Therapy in Adult ALL.
Blood cancer discovery
Review2026 - Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy.
Nature communications
Article2026 - Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis.
Bone marrow transplantation
Article2026 - Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations.
American journal of hematology
Guideline2026
Most-cited works
by citation count (OpenAlex)- 01The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaArticle489 citations2023
- 02
- 03Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaArticle325 citations2020
- 04Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemiaArticle301 citations2016
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ibrahim-aldoss-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/ibrahim-aldoss-0b82b1b6
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Ibrahim-Aldoss-15549128
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
cityofhope.org/people/aldoss-ibrahim
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
Jordan University of Science and Technology (Irbid, Jordan)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗ - Internal medicine residency
Creighton University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗ - Hematology/oncology fellowship
Keck School of Medicine of USC (served as chief hematology fellow and clinical instructor)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗ - Board-certified in internal medicine
medical oncology, and hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jnccn.org ↗
- Physician co-leader
Leukemia Disease Team, City of Hope
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗ - Co-director
Acute Lymphoblastic Leukemia (ALL) Program, City of Hope
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cityofhope.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →jnccn.org ↗
Media & interviews
press, podcasts and appearances- Regular video interview contributor
VJHemOnc (Video Journal of Hematology and Hematological Oncology), e.g. AUGMENT-101 trial: revumenib in R/R KMT2A-rearranged acute leukemia
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗ - OncLive On Air podcast guest
discussed ponatinib monotherapy after combination chemotherapy in newly diagnosed Ph+ ALL
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Sumanta Pal, MD
City of Hope National Medical Center
Joanne Mortimer, MD
City of Hope National Medical Center
Tanya Dorff, MD
City of Hope National Medical Center
Alex Herrera, MD
City of Hope National Medical Center